ArticleJournal of virology2007
Ebola virus VP30 is an RNA binding protein.
Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 69 citations in OpenAlex.
- Development of VP30-targeted nanoparticles using DPS4 fusion peptides for the inhibition of Ebola virus.Journal of nanobiotechnology · 2026Article
- Mapping Immunological, Host Receptor Binding Determinants, and Cathepsin Cleavage Site of EBOV Glycoprotein Utilizing the Qubevirus Platform.ACS omega · 2025Article
- Biophysical Characterization of the MMethods in molecular biology (Clifton, N.J.) · 2025Article
- RNA-protein interaction prediction without high-throughput data: An overview and benchmark ofComputational and structural biotechnology journal · 2024Article
- The cellular protein phosphatase 2A is a crucial host factor for Marburg virus transcription.Journal of virology · 2024Article
- Article
- Article
- Predicting Protein Conformational Disorder and Disordered Binding Sites.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Structural and Functional Aspects of Ebola Virus Proteins.Pathogens (Basel, Switzerland) · 2021Review
- Non-canonical proline-tyrosine interactions with multiple host proteins regulate Ebola virus infection.The EMBO journal · 2021Article
- Article
- Distinct Genome Replication and Transcription Strategies within the Growing Filovirus Family.Journal of molecular biology · 2019Review
- Virus and host interactions critical for filoviral RNA synthesis as therapeutic targets.Antiviral research · 2019Review
- Protein Interaction Mapping Identifies RBBP6 as a Negative Regulator of Ebola Virus Replication.Cell · 2018Article
- Unconventional RNA-binding proteins step into the virus-host battlefront.Wiley interdisciplinary reviews. RNA · 2018Review
- Ebolaviruses: New roles for old proteins.PLoS neglected tropical diseases · 2018Review
- Curcumin and Natural Derivatives Inhibit Ebola Viral Proteins: AnPharmacognosy research · 2017Article
- Ebola virus VP30 and nucleoprotein interactions modulate viral RNA synthesis.Nature communications · 2017Article
- The Ebola Virus VP30-NP Interaction Is a Regulator of Viral RNA Synthesis.PLoS pathogens · 2016Article
- RNA binding specificity of Ebola virus transcription factor VP30.RNA biology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Ebola virus (EBOV) genome encodes for several proteins that are necessary and sufficient for replication and transcription of the viral RNAs in vitro; NP, VP30, VP35, and L. VP30 acts in trans with an RNA secondary structure upstream of the first transcriptional start site to modulate transcription. Using a bioinformatics approach, we identified a region within the N terminus of VP30 with sequence features that typify intrinsically disordered regions and a putative RNA binding site. To experimentally assess the ability of VP30 to directly interact with the viral RNA, we purified recombinant EBOV VP30 to >90% homogeneity and assessed RNA binding by UV cross-linking and filter-binding assays. VP30 is a strongly acidophilic protein; RNA binding became stronger as pH was decreased. Zn(2+), but not Mg(2+), enhanced activity. Enhancement of transcription by VP30 requires a RNA stem-loop located within nucleotides 54 to 80 of the leader region. VP30 showed low binding affinity to the predicted stem-loop alone or to double-stranded RNA but showed a good binding affinity for the stem-loop when placed in the context of upstream and downstream sequences. To map the region responsible for interacting with RNA, we constructed, purified, and assayed a series of N-terminal deletion mutations of VP30 for RNA binding. The key amino acids supporting RNA binding activity map to residues 26 to 40, a region rich in arginine. Thus, we show for the first time the direct interaction of EBOV VP30 with RNA and the importance of the N-terminal region for binding RNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.